IFRX

InflaRx NV

Add to Watchlist

Advanced Chart

0.830

+0.029(3.624%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

0.840

Open

0.8207

VWAP

0.81

Vol

242.45K

Mkt Cap

47.12M

Low

0.7895

Amount

196.79K

EV/EBITDA(TTM)

Total Shares

58.88M

-24.03M

EV/OCF(TTM)

P/S(TTM)

259.54

Inflarx NV, formerly Fireman BV, is a holding company for InflaRx GmbH, a Germany-based clinical-stage biopharmaceutical company. The Company's primary focus is on the development of monoclonal antibodies targeting activation products of the complement system for application in the treatment of life-threatening inflammatory diseases. Its lead product candidate, IFX-1, is an intravenously delivered first-in-class anti-C5a monoclonal antibody, undergoing Phase II clinical trial for the treatment of Hidradenitis Suppurativa (HS), a rare and chronic debilitating systemic inflammatory skin disease, and entering Phase II clinical trial for the treatment of ANCA-associated vasculitis (AAV) and other rare autoimmune diseases. The Company's product pipeline also includes IFX-2, which is in preclinical development.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

28.20K

-6814.29%

-0.130

-0%

25.40K

-79.49%

-0.133

+66.66%

21.80K

+242.77%

-0.140

-53.33%

Estimates Revision

The market is revising No Change the revenue expectations for InflaRx N.V. (IFRX) for FY2025, with the revenue forecasts being adjusted by 0% over the past three months. During the same period, the stock price has changed by -50.32%.

Revenue Estimates for FY2025

No Change

0.00%

In Past 3 Month

EPS Estimates for FY2025

Revise Downward

-12.5%

In Past 3 Month

Stock Price

Go Down

-50.32%

In Past 3 Month

6 Analyst Rating

333.94% Upside

Wall Street analysts forecast IFRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IFRX is 3.60 USD with a low forecast of 1.00 USD and a high forecast of 10.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

4 Buy

2 Hold

0 Sell

Moderate Buy

333.94% Upside

Current: 0.830

Low

1.00

Averages

3.60

High

10.00

333.94% Upside

Current: 0.830

Low

1.00

Averages

3.60

High

10.00

Raymond James

Strong Buy -> Outperform

downgrade

$13 -> $2

2025-05-29

Reason

Raymond James

Price Target

$13 -> $2

2025-05-29

downgrade

Strong Buy -> Outperform

Reason

Raymond James downgraded InflaRx to Outperform from Strong Buy with a price target of $2, down from $13, after the Independent Data Monitoring Committee recommended the Phase 3 trial evaluating vilobelimab in pyoderma gangrenosum be stopped at the interim futility analysis due to lack of observed treatment effect. The firm's Our investment thesis is now primarily focused on the INF904 programs for which it has a positive outlook. However, given their relatively early stage, Raymond James dramatically reduced its price target, driven by the relatively higher level of uncertainty prior to their proof-of-concept basket study readout.

Oppenheimer

Andreas Argyrides

Outperform -> NULL

downgrade

$6 -> $3

2025-05-29

Reason

Oppenheimer

Andreas Argyrides

Price Target

$6 -> $3

2025-05-29

downgrade

Outperform -> NULL

Reason

Oppenheimer analyst Andreas Argyrides lowered the firm's price target on InflaRx to $3 from $6 and keeps an Outperform rating on the shares. The firm notes InflaRx has announced that the IDMC recommended stopping the Phase 3 trial for vilobelimab, anti-C5a mAb, in PG due to futility following an unblinded interim analysis in 30 patients. With the discontinuation of vilo/PG, Oppenheimer removes it from its valuation as InflaRx shifts focus and resources to oral potent C5aR inhibitor, INF904 in HS and CSU.

Guggenheim

Yatin Suneja

Strong Buy

Maintains

$7 → $10

2025-03-26

Reason

Guggenheim

Yatin Suneja

Price Target

$7 → $10

2025-03-26

Maintains

Strong Buy

Reason

Guggenheim raised the firm's price target on InflaRx to $10 from $7 and keeps a Buy rating on the shares. All programs remain on track following the Q4, notes the analyst, who is "encouraged" by the updates from both vilobelimab and INF904. Once the company reports interim data for both ongoing programs, investors should "begin to realize the significant opportunity for the company," the analyst argues.

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

2025-03-21

Reason

HC Wainwright & Co.

Edward White

Price Target

2025-03-21

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

2025-03-07

Reason

HC Wainwright & Co.

Edward White

Price Target

2025-03-07

Reiterates

Strong Buy

Reason

HC Wainwright & Co.

Edward White

Strong Buy

Reiterates

2025-01-16

Reason

HC Wainwright & Co.

Edward White

Price Target

2025-01-16

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for InflaRx NV (IFRX.O) is -1.64, compared to its 5-year average forward P/E of -2.52. For a more detailed relative valuation and DCF analysis to assess InflaRx NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-2.52

Current PE

-1.64

Overvalued PE

-1.39

Undervalued PE

-3.64

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-1.13

Current EV/EBITDA

0.00

Overvalued EV/EBITDA

1.96

Undervalued EV/EBITDA

-4.23

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

N/A

5Y Average PS

1835.54

Current PS

180.88

Overvalued PS

8976.11

Undervalued PS

-5305.03